Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Lead Testing Pregnancy topic
No spam. Unsubscribe anytime.
Senate committee advances bill to require targeted lead testing in pregnancy
Summary
A Senate Health Committee on Tuesday released S3616 after testimony urging prenatal lead testing to identify exposure tied to preeclampsia and other adverse outcomes; amendments align testing with CDC and ACOG guidance and call for baseline and third‑trimester checks when risk is present.
The Senate Health Committee released S3616 on a voice roll call after extended testimony from public‑health advocates who said prenatal lead testing could help prevent pregnancy complications. Elise Pivnick, senior advisor at Isles, Inc., told the committee that "lead is considered, the most direct factor we know associated with preeclampsia" and urged two tests — a baseline and one in the third trimester — for people with a history suggesting exposure.
Proponents said the test is inexpensive, can use an additional vial when blood is already drawn for routine pregnancy labs, and allows clinicians and families to intervene earlier. Pivnick said lead stored in bone can be remobilized during pregnancy and is associated with preterm birth, impaired fetal growth and hypertensive complications.
Committee amendments revised the bill’s scope to apply to a broader set of licensed health professionals who provide prenatal care and shifted the standard from a rigid schedule to testing based on the latest CDC and American College of Obstetricians and Gynecologists (ACOG) recommendations. The amendment also stipulates that a health professional is not required to re‑test if another qualified professional has already completed the required testing.
Members asked technical questions about logistics and confidentiality. Senator Chapizi raised concerns that many obstetrics practices send blood draws to offsite laboratories and asked whether the bill’s referral language should explicitly include laboratory facilities; proponents replied that the test can be added to existing lab draws and that referral language can be clarified.
The committee also discussed reporting: one senator raised a potential inconsistency between a section that mandates reporting results to the local health department and another section that includes confidentiality provisions; the senator said he would speak with the sponsor to ensure the language does not run afoul of HIPAA. Committee staff indicated they would review and tighten language as needed.
The committee approved the release of S3616 as amended. Next steps for the bill include any further amendment drafting requested by the sponsor and scheduling for floor consideration.
